Sonja Ständer, EADV 2021: Nemolizumab in the Treatment of Prurigo Nodularis
Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) kindly took the time to speak to us about the health burden of prurigo and recent investigations into the IL-31 targeted therapy, nemolizumab.
Her presentation entitled ‘Nemolizumab rapidly relieves itch and sleep disturbances in patients with prurigo nodularis’ was given at the EADV 30th Congress, 29 Sep – 2 Oct.
Questions
- Could you tell us a little about prurigo nodularis and its health burden? (0:11)
- Why has interleukin-31 become a clinical target for chronic pruritus and prurigo treatment? (0:59)
- What were the aims and design of the clinical study you are presenting? (1:45)
- What were the clinical endpoints and how well were these achieved? (2:24)
- Could you tell us a little about the safety profile of nemolizumab? (2:54)
Disclosures: Prof. Sonja Ständer has received consultancy, advisory board and speaker fees from Galderma and also acted as an investigator for Galderma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
